Free Trial

Aptose Biosciences (TSE:APS) Share Price Crosses Below 50 Day Moving Average - Here's Why

Aptose Biosciences logo with Medical background

Aptose Biosciences Inc. (TSE:APS - Get Free Report) NASDAQ: APTO shares passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of C$2.64 and traded as low as C$2.38. Aptose Biosciences shares last traded at C$2.38, with a volume of 2,100 shares changing hands.

Analyst Ratings Changes

Separately, Alliance Global Partners raised shares of Aptose Biosciences to a "strong-buy" rating in a research report on Thursday, February 27th.

Get Our Latest Analysis on APS

Aptose Biosciences Price Performance

The company has a quick ratio of 5.41, a current ratio of 1.05 and a debt-to-equity ratio of -117.37. The business's 50-day moving average is C$2.64 and its two-hundred day moving average is C$5.70. The company has a market capitalization of C$102.48 million, a P/E ratio of -0.47 and a beta of 1.36.

About Aptose Biosciences

(Get Free Report)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Aptose Biosciences Right Now?

Before you consider Aptose Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aptose Biosciences wasn't on the list.

While Aptose Biosciences currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Oil Spikes Amid Rising Warfare: 3 Stocks to Watch Now
Palantir at All-Time Highs: Take Profits or Hold the Line?
3 Tech Stocks Insiders Are Buying: Speculative Plays for June

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines